InMed Pharmaceuticals Inc (INM)

[Flair09]

IMLFF (InMed Pharmaceuticals Inc.) is our New Epic Pick!
Last Price: .29  |  SEC Filings  |  Latest News

Begin your research at https://www.inmedpharma.com


Some of you might remember the last time we profiled Today's Alert back in February.

After little more than 1 month, it went on to stage a Historic Rally, printing New ALL-TIME HIGHS, and delivering as much as 166% GAINS to the Wolfpack!

Now it's back trading at those very same prices from where it rallied with some Major New Developments and operating in a social landscape that includes 8 STATES that have fully legalized Marjuana and a MAJORITY of the entire US Population (28 States) that now has access to MEDICALMarjuana!

So let's head back into the wild world of the Medical Marjuana Sector with a company that is truly head and shoulders above the rest.


[Re]Introducing....IMLFF!


IMLFF HAS PROVEN TO BE OUR BIGGEST MEDICAL MARJUANA ALERT OF THE YEAR.

Dual-listed on the OTCQB and CSE Exchange (IN.V) in Canada, IMLFF is a pre-clinical stage Biopharmaceutical company that specializes in developing therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

IMLFF is taking a very unique approach to treatment through Canna.bis.   Where most others research the most easily isolated cannabinoid of THC, IMLFF has developed a process and tool to enable research of the disease-fighting effects of ALL 90+ CANNABINOIDS that exist.

Not only is IMLFF's scientific discovery amazing...it could potentially be REVOLUTIONARY in discovering ALL the treatment, healing, and curing possibilities from every part of the Canna.bis plant.

Already in the pipeline for the company are two therapies to tackle Glaucoma and Epidermolysis Bullosa - a potential market of over $6 BILLION per year.

So it's no surprise that IMLFF has attracted Execs from Pharmaceutical & Biotech Powerhouses such as Eli Lilly and GW Pharmaceuticals!  Even FORBES has raved about this company!  This is a true test of how SERIOUS this company is.

So could IMLFF be ready for another Historic run?  Let's take a look.



IMLFF TRIANGLE PATTERN - REVERSAL IMMINENT?
IMLFF has certainly been on a phenomenal run since the Election.

After our reaching New All-Time Highs of .72 after our last alert, IMLFF began it's slow descent back to the same levels it rallied from last time and now displays TWO potentially Major Technical Signals:

An Ascending Triangle Pattern and a GOLDEN CROSS of the 50 & 200 Day Moving Averages!

With so much in the pipeline, could IMLFF stage another epic BREAKOUT of this pattern and capture New All-Time Highs again?  See below...



IMLFF - REVOLUTIONIZING MEDICAL MARJUANA
InMed Pharmaceuticals (IMLFF) is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.


SO WHAT ARE CANNABINOIDS?
Cannabinoids are a group of active compounds found in marjuana that are responsible for it's effects on the body and the reason why medical marjuana works to alleviate so many symptom-related ailments from Cancer to inflammation and more. 

Canna.bis produces 90+ individual cannabinoids. The most well known are THC and CBD.

What most are unaware of is that the HUMAN BODY naturally produces endo-cannabinoids and has receptors that interact with those from the plant which effect everything from metabolism to pain!


WHY IMLFF?
IMLFF is still a relatively small company - but with a single BIG idea:  use biosynthesis to create the cannabinoids found in tiny amounts in naturally grown marjuana.

InMed has developed and patented a technologically advanced process to isolate the active cannabinoids and produce them biosynthetically.

This enables the research of the disease-fighting effects of ALL 90+ Cannabinoids - not just THC and CBD which is what most others are researching!

Advantages of InMed’s Bioinformatics Tool

Generates new therapies both quickly and effectively - significant cost and time savings in discovery process.Allows InMed to research pharmacological responses of ALL 90+ cannabinoids.Has already identified multiple therapies including InMed’s INM-750 & INM-085.


The potential competitive advantage here could be ENORMOUS!


To truly understand what IMLFF is all about, you MUST check out this Company Explanation Video + Interview with the CEO courtesy of BNN.






SO WHAT'S IN THE PIPELINE?
So far IMLFF's bioinformatics assessment has been used to identify two disease development programs:

INM-750 for Epidermolysis Bullosa – An orphan pediatric disease characterized by extremely fragile skin with no current approved therapies.  Potential of $1 BIL/year

INM-750 targets cannabinoid receptors in the skin to deliver symptomatic relief:

    1) Accelerated wound healing   2) pain & itch reduction   3)  reduce inflammation
    4)  antimicrobial activity  5) may REVERSE the disease

INM-085 for Glaucoma – A serious eye disease with a global market of $5 BIL+/year

INM-085 is a combination of cannabinoids selected to:
1) Reduce the intraocular pressure in the affected eyes  2)  Provide neuroprotection for the retinal ganglion cells

In May, IMLFF filed a patent for new ophthalmic drug delivery technology - essentially Hydrogel Eye Drops developed as a once a day treatment for glaucoma!




CONSIDER THIS...
A century ago, a diabetes diagnosis was basically a death sentence. 

Then in the early 1970s, a tiny and innovative biotech company found that it could combine strains of E. coli bacteria with human genes to produce what’s called a “biosynthetic insulin.”

That small company was Genentech who ended up partnering with Eli Lilly to produce biosynthetic insulin,  turning it into a $35 BIL a year industry today!

Eli Lilly is now a $73 billion pharmaceutical giant.

Now, IMLFF is targeting the exact same thing as Genentech within the Canna.bis industry WITH an Eli Lilly executive on board!



ALSO CONSIDER...

GW Pharmaceuticals (GWPH) successfully isolated a particular part of the marjuana plant and brought to market a multiple sclerosis treatment that’s approved for use in dozens of countries.

GW's success in developing pharmaceutical drugs from marjuana has sent its shares from less than $9 in 2013 to more than $105 today with a market value of more than $2.6 billion!!!

GW Pharma has only identified 14 or so Cannabinoids to develop therapies with and their method of extraction is time consuming and costly.

IMLFF, on the other hand, has a tool that can potentially identify all 90+ Cannabinoids!!

So it's no wonder why IMLFF's Chief Medical Officer jumped ship from GW Pharmaceuticals where he previously served as an Associate Medical Director!



THE BOTTOM LINE
It's no surprise that so many are calling IMLFF the "Next GW Pharmaceuticals (GWPH)"!  See here and here.

IMLFF is continuously making new strides - especially in the pre-clinical testing of their Pain Treatment Program.  And best of all, they are upfront and direct with shareholders, regularly releasing Updates and News like last week's Big Update.

With a potential BREAKOUT Chart, a strong management team, a potentially revolutionary process, and treatments now in pre-clinical testing, there may be NO BETTER TIME to check out IMLFF than right now!

If you missed IMLFF the first time...DO NOT MISS IT AGAIN!   Make sure you put it on your screen RIGHT NOW and Follow on Twitter for Updates + Play-by-Play!

Good Trading,
EpicStockPicks.com


Need an Online Broker to place trades?  We recommend FIRSTRADE!